[go: up one dir, main page]

CN1386524A - A Chinese medicinal composition for treating cancer - Google Patents

A Chinese medicinal composition for treating cancer Download PDF

Info

Publication number
CN1386524A
CN1386524A CN 01118222 CN01118222A CN1386524A CN 1386524 A CN1386524 A CN 1386524A CN 01118222 CN01118222 CN 01118222 CN 01118222 A CN01118222 A CN 01118222A CN 1386524 A CN1386524 A CN 1386524A
Authority
CN
China
Prior art keywords
raw materials
horn
chinese medicine
traditional chinese
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 01118222
Other languages
Chinese (zh)
Other versions
CN1141126C (en
Inventor
欧应贤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB011182229A priority Critical patent/CN1141126C/en
Publication of CN1386524A publication Critical patent/CN1386524A/en
Application granted granted Critical
Publication of CN1141126C publication Critical patent/CN1141126C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

本发明涉及一种治疗癌症的中药组合物,其原料组成为犀角、牛黄、山慈姑、板蓝根、蒲公英、白花蛇舌草、龙葵、连翘、穿山甲、麝香、蚤休、川贝、赤芍、天丁、夏枯草、昆布、蕨根、西洋参、当归、熟地、白芍、丹参、大黄、茵陈、天葵子、土茯苓、八角莲,如有积水配合使用醋大戟、米炒斑蝥,否则不用。The invention relates to a traditional Chinese medicine composition for treating cancer, the raw materials of which are composed of rhino horn, bezoar, sagittaria, isatidis, dandelion, hedyotis diffusa, solanum nigrum, forsythia, pangolin, musk, flea, chuanbei, red peony , Tianding, Prunella vulgaris, Kelp, Fern root, American ginseng, Angelica, Rehmannia glutinosa, Radix Paeoniae Alba, Salvia miltiorrhiza, Rhubarb, capillary, geranium seed, Smilax cocos, Star anise lotus, if there is stagnant water, use vinegar euphorbia, rice stir-fry Mylabris, otherwise don't use it.

Description

一种治疗癌症的中药组合物A kind of traditional Chinese medicine composition for treating cancer

本发明涉及一种治疗癌症的中药组合物,具有清热解毒、化痰散节、消瘀软坚、补气活血养血、消肿通淋、驱邪生肌的功效。The invention relates to a traditional Chinese medicine composition for treating cancer, which has the effects of clearing heat and detoxifying, dispelling phlegm and dispelling joints, eliminating blood stasis and softening hardness, invigorating qi, activating blood and nourishing blood, reducing swelling and treating stranguria, expelling evil and promoting muscle growth.

癌症是当前危害人类健康的凶恶杀手。人体多由于受各种内、外界因素的影响,导致气血失调,痰瘀交阻,热毒凝结,而致气血凝滞,痰瘀互结不化形成癌症。中医采取清热解毒、化痰止痛、补气活血养血、消瘀软坚散节、扶正祛邪而治之。Cancer is a vicious killer currently endangering human health. The human body is mostly affected by various internal and external factors, leading to Qi and blood imbalance, phlegm and blood stasis intertwining, heat and toxin coagulation, resulting in Qi and blood stagnation, phlegm and blood stasis intertwining and forming cancer. Traditional Chinese medicine treats it by clearing heat and detoxifying, reducing phlegm and relieving pain, invigorating qi, activating blood and nourishing blood, eliminating blood stasis, softening hardness and loosening joints, strengthening the body and eliminating pathogenic factors.

本申请的目的就是提供一种治疗癌症的中药组合物。申请人在40年临床研究的基础上,根据中医扶正祛邪的原则,组成此组合物,它可以增强人体免疫系统的功能,抑制癌症生长,消肿散节排毒,化腐生肌止痛,提高患者的生存质量,延长生命,能够用于治疗各种癌症。本申请的中药组合物原料的通常重量比为(1)犀角2、牛黄0.4、麝香0.2、西洋参4-5,及(2)山慈姑3-6、板蓝根5-10、蒲公英5-10、白花蛇舌草10-15、龙葵10-15、连翘5-10、穿山甲3-6、蚤休3-15、川贝3-10、赤芍5-10、天丁2-5、夏枯草3-10、昆布5-15、蕨根5-15、当归5-15、熟地5-15、白芍5-15、丹参5-15、大黄2-15、茵陈5-15、天葵子5-10、土茯苓5-10、八角莲3-10。在临床使用中可以根据具体病情适当调整其中各组分的用量。此组合物的原料优选的重量配比为(1)犀角2、牛黄0.4、麝香0.2、西洋参4,及(2)山慈姑3、板蓝根4、蒲公英4、白花蛇舌草5、龙葵6、连翘3、穿山甲3、蚤休4、川贝3、赤芍4、天丁2、夏枯草3、昆布4、蕨根4、当归5、熟地4、白芍4、丹参4、大黄2、茵陈4、天葵子4、土茯苓3、八角莲4。The purpose of this application is to provide a Chinese medicine composition for treating cancer. On the basis of 40 years of clinical research, the applicant composed this composition according to the principle of strengthening the body and eliminating pathogenic factors in traditional Chinese medicine. It can enhance the function of the human immune system, inhibit cancer growth, reduce swelling, loosen joints and detoxify, reduce putrefaction, promote muscle and relieve pain, and improve the health of patients. quality of life, prolong life, and can be used to treat various cancers. The usual weight ratio of the raw materials of the traditional Chinese medicine composition of the present application is (1) rhinoceros horn 2, bezoar 0.4, musk 0.2, American ginseng 4-5, and (2) Arthia chinensis 3-6, Radix isatidis 5-10, Dandelion 5-10, white flower Hedyotis 10-15, Solanum nigrum 10-15, Forsythia 5-10, Pangolin 3-6, Lixiu 3-15, Chuanbei 3-10, Radix Paeoniae Rubra 5-10, Astragalus 2-5, Prunella vulgaris 3-10, kelp 5-15, fern root 5-15, angelica 5-15, rehmannia 5-15, white peony 5-15, salvia miltiorrhiza 5-15, rhubarb 2-15, capillary 5-15, tiankuizi 5-10, Smilax 5-10, Star anise 3-10. In clinical use, the dosage of each component can be appropriately adjusted according to the specific condition. The preferred weight ratio of the raw materials of this composition is (1) rhinoceros horn 2, bezoar 0.4, musk 0.2, American ginseng 4, and (2) Arthia chinensis 3, Radix isatidis 4, dandelion 4, Hedyotis diffusa 5, Solanum nigrum 6, Forsythia 3, Pangolin 3, Flea Xiu 4, Chuanbei 3, Chishao 4, Tianding 2, Prunella vulgaris 3, Kelp 4, Fern root 4, Angelica 5, Rehmannia glutinosa 4, Paeoniae Alba 4, Salvia miltiorrhiza 4, Rhubarb 2, Yinchen 4, Tiankuizi 4, Smilax 3, Star anise 4.

本组合物的方解为:The solution of this composition is:

1.清热解毒,散结者为君药1. Clearing away heat and detoxification, the one that dissipates stagnation is the king medicine

犀角、牛黄、山慈姑、板蓝根、蒲公英、白花蛇舌草、龙葵、连翘、八角莲Rhino horn, bezoar, Arthia chinensis, isatid root, dandelion, hedyotis diffusa, black nightshade, forsythia, star anise lotus

2.化痰散瘀软坚者为臣药2. Those who resolve phlegm, dissipate blood stasis and soften hardness are ministerial medicines

麝香、穿山甲、赤芍、川贝、天丁、蚤休、夏枯草、蕨根、昆布Musk, pangolin, red peony, Chuanbei, Tianding, flea, Prunella, fern root, kelp

3.补气活血、养血、止痛者为佐药3. It is adjuvant medicine for invigorating qi, promoting blood circulation, nourishing blood and relieving pain

西洋参、当归、熟地、白芍、丹参American ginseng, angelica, rehmannia root, white peony root, salvia miltiorrhiza

4.消肿通淋者为使药4. It is used for reducing swelling and treating stranguria

大黄、茵陈、天葵子、土茯苓Rhubarb, capillary, geranium, smilax

本申请中药组合物的制备方法如下The preparation method of the application Chinese medicine composition is as follows

将第(1)组原料犀角、牛黄、麝香、西洋参粉碎;将第(2)组原料山慈姑、板蓝根、蒲公英、白花蛇舌草、龙葵、连翘、穿山甲、蚤休、川贝、赤芍、天丁、夏枯草、昆布、蕨根、当归、与第(1)组原料混合,制成片剂、散剂、冲剂或胶囊,或与第(1)组原料混合后,加蜜制成丸剂。Grind rhino horn, bezoar, musk, and American ginseng as raw materials in group (1); Arthia chinensis, Banlangen, dandelion, hedyotis diffusa, nightshade, forsythia, pangolin, flea, Chuanbei, red Paeoniae officinalis, Tianding, Prunella vulgaris, Kelp, fern root, angelica, mixed with the raw materials of group (1), made into tablets, powders, granules or capsules, or mixed with the raw materials of group (1), and made by adding honey pill.

组合物中所用犀角可以用水牛角10-15重量份代替。优选用量是15重量份且作为第(2)组原料。The rhino horn used in the composition can be replaced by 10-15 parts by weight of buffalo horn. The preferred amount is 15 parts by weight and as a group (2) raw material.

如有积水,用醋大戟2g和米炒斑蝥0.05g制成胶囊,配合使用,但无积水,血瘀者禁用此胶囊。If there is stagnant water, make a capsule with 2 g of Euphorbia euphorbia in vinegar and 0.05 g of rice-fried mylabris, and use it together, but this capsule is contraindicated for those without stagnant water and blood stasis.

本申请中药组合物的另一服用方法是:将第(1)组原料粉碎制成散剂,将第(2)组原料制成汤剂,早晨服散剂,中午服汤剂,晚上服大戟和斑蝥制成的胶囊。Another method of taking the Chinese medicine composition of the present application is: pulverize the raw materials of the (1) group to make powder, make the decoction of the raw materials of (2), take the powder in the morning, take the decoction at noon, and take Euphorbia and Capsules made from Mylabris.

另外用田螺膏、万灵膏、生肌粉敷患部,及针灸患部,可以增强本申请药物的疗效。In addition, apply the snail ointment, Wanling ointment, muscle-promoting powder to the affected part, and acupuncture the affected part, which can enhance the curative effect of the medicine of this application.

治疗期间禁食海腥、萝卜、牛、羊、鹅、鸡、猪肝、瘦肉等生痰生火之物。During the treatment period, fasting seafood, radish, cattle, sheep, goose, chicken, pork liver, lean meat and other things that produce phlegm and fire.

实施例:按以下重量取原料,(1)犀角2g、牛黄0.4g、麝香0.2g、西洋参4g,粉碎制成散剂,(2)山慈姑3-6g、板蓝根5-10g、蒲公英5-10g、白花蛇舌草10-15g、龙葵10-15g、连翘5-10g、穿山甲3-6g、蚤休3-15、川贝3-10g、赤芍5-10g、天丁2-5g、夏枯草3-10g、昆布5-15g、蕨根5-15g、当归5-15g、熟地5-15g、白芍5-15g、丹参5-15g、大黄2-15g、茵陈5-15g、天葵子5-10g、土茯苓5-10g、八角莲3-10g,煎成汤剂,(3)以醋大戟2g和米炒斑蝥0.05g制成胶囊。Embodiment: get raw material by following weight, (1) rhinoceros horn 2g, bezoar 0.4g, musk 0.2g, American ginseng 4g, pulverize and make powder, (2) Arthia chinensis 3-6g, Radix Radix 5-10g, Dandelion 5-10g, Hedyotis diffusa 10-15g, Solanum solanum 10-15g, Forsythia 5-10g, Pangolin 3-6g, Flea Xiu 3-15, Chuanbei 3-10g, Radix Paeoniae Rubra 5-10g, Tianding 2-5g, Xia Subtilis 3-10g, Kelp 5-15g, Fern root 5-15g, Angelica 5-15g, Rehmannia glutinosa 5-15g, Paeoniae Alba 5-15g, Salvia miltiorrhiza 5-15g, Rhubarb 2-15g, Capillary 5-15g, Tiankui 5-10g of seeds, 5-10g of soil tuckahoe, 3-10g of star anise lotus, decocted into a decoction, (3) make capsules with 2g of Euphorbia euphorbia in vinegar and 0.05g of fried mylabris with rice.

以上为每人每天的服用量,早晨服散剂,中午服汤剂,晚上服胶囊。The above is the dosage per person per day. Take powder in the morning, decoction at noon, and capsule in the evening.

本申请的药物经多年临床使用,能够有效消除临床症状,疗效可靠,且远期疗效好,复发率低。除孕妇应慎用外,无毒副作用。以下是临床观察总结:After many years of clinical use, the medicine of the present application can effectively eliminate clinical symptoms, has reliable curative effect, good long-term curative effect and low recurrence rate. Except that pregnant women should use it with caution, it has no toxic side effects. The following is a summary of clinical observations:

一.一般资料  本药物多年来自制使用,治疗的患者从二十几岁至七十余岁。均经CT检查、切片、化验等临床手段证实为癌症。现收集100例胃癌、食管癌病例加以统计,以成年门诊病人为观察对象。1. General information This drug has been used by self-made for many years, and the patients treated are from their twenties to their seventies. All were confirmed as cancer by clinical methods such as CT examination, section, and laboratory tests. 100 cases of gastric cancer and esophageal cancer are collected for statistics, and adult outpatients are taken as observation objects.

二.治疗方法  服用本申请药物组合物的丸剂,按实施例的剂量每日分3次服用,每一个月为一疗程,一般服药2-6个月。2. Therapeutic method Take the pill of the pharmaceutical composition of the present application, and divide it into 3 times a day according to the dosage of the embodiment, and each month is a course of treatment, generally taking the medicine for 2-6 months.

三.疗效评定标准  采用自身治疗前后症状对比,按抗癌药物临床研究指导原则实体瘤客观疗效评定标准评定观察效果,3. Efficacy evaluation standard Use the comparison of symptoms before and after self-treatment, and evaluate the observation effect according to the guidelines for clinical research of anticancer drugs and solid tumor objective efficacy evaluation standards.

临床治愈  症状及检查的阳性体征消失,恢复一定的劳动能力。Clinical cure Symptoms and positive signs of examination disappear, and a certain ability to work is restored.

显效  症状基本消失,病灶缩小,身体检查的各项指标好转。Significantly effective Symptoms basically disappeared, lesions shrunk, and various indicators of physical examination improved.

有效  症状有所改善,病灶基本稳定。Effective Symptoms were improved, and the lesion was basically stable.

经观察,服药后大部分病人症状明显减轻或消失,食欲增加,生存质量得到提高,部分病人观察到瘤体缩小,经统计显效率15%,有效率46%,总有效率为61%。It was observed that after taking the medicine, the symptoms of most patients were significantly relieved or disappeared, the appetite increased, and the quality of life was improved. Some patients observed that the tumor size shrank. The statistically significant rate was 15%, the effective rate was 46%, and the total effective rate was 61%.

本药物治疗其他癌症也收到较好的效果。This medicine also receives good effect in treating other cancers.

典型病例Typical cases

1、王林  男,71岁,老红军。1986年经CT检查,膀胱右侧有1.7×1.2厘米的肿块,确诊为膀胱癌,经多个医院治疗无效。1986年10月来我所治疗。经查:体瘦面黄,苍白,苔黄厚,脉沉数有利,口干,大便正常,小便血红色,每天尿10余次。此人早几年切除,手摸患处微痛,患部微红肿,有硬块1个。在我所服药治疗30天后,小便正常,能下床,再服150天后,行动自由,肿块消失,恢复健康。1995年回访,患者正常。1. Wang Lin Male, 71 years old, veteran of the Red Army. In 1986, after CT examination, there was a mass of 1.7×1.2 cm on the right side of the bladder, which was diagnosed as bladder cancer, and the treatment by several hospitals failed. He came to our clinic for treatment in October 1986. After investigation: thin body, pale face, yellow and thick fur, favorable pulse, dry mouth, normal stool, red urine, more than 10 times a day. This person had been removed several years ago, and the affected area was slightly painful to touch, and the affected area was slightly red and swollen, with 1 hard lump. After 30 days of treatment with the medicine I took, my urine was normal and I was able to get out of bed. After taking it for another 150 days, I could move freely, the lumps disappeared, and I was back to health. Return visit in 1995, the patient is normal.

Claims (9)

1、一种治疗癌症的中药组合物,其特征在于它是由以下两组重量配比的原料制成的:(1)犀角2、牛黄0.4、麝香0.2、西洋参4-5;及(2)山慈姑3-6、板蓝根5-10、蒲公英5-10、白花蛇舌草10-15、龙葵10-15、连翘5-10、穿山甲3-6、蚤休3-15、川贝3-10、赤芍5-10、天丁2-5、夏枯草3-10、昆布5-15、蕨根5-15、当归5-15、熟地5-15、白芍5-15、丹参5-15、大黄2-15、茵陈5-15、天葵子5-10、土茯苓5-10、八角莲3-10。1. A traditional Chinese medicine composition for treating cancer, characterized in that it is made of the following two groups of raw materials in weight ratio: (1) rhino horn 2, bezoar 0.4, musk 0.2, American ginseng 4-5; and (2) Arthia chinensis 3-6, Banlangen 5-10, Dandelion 5-10, Hedyotis diffusa 10-15, Nightshade 10-15, Forsythia 5-10, Pangolin 3-6, Flea 3-15, Chuanbei 3 -10, Chishao 5-10, Tianding 2-5, Prunella vulgaris 3-10, Kelp 5-15, Fern root 5-15, Angelica 5-15, Rehmannia glutinosa 5-15, Baishao 5-15, Salvia 5 -15, rhubarb 2-15, capillary 5-15, geranium 5-10, smilax 5-10, star anise 3-10. 2、根据权利要求1所述的中药组合物,其特征在于此组合物的原料组成为:(1)犀角2、牛黄0.4、麝香0.2、西洋参4;及(2)山慈姑3、板蓝根4、蒲公英4、白花蛇舌草5、龙葵6、连翘3、穿山甲3、蚤休4、川贝3、赤芍4、天丁2、夏枯草3、昆布4、蕨根4、当归5、熟地4、白芍4、丹参4、大黄2、茵陈4、天葵子4、土茯苓3、八角莲4。2. The traditional Chinese medicine composition according to claim 1, characterized in that the raw materials of the composition consist of: (1) rhino horn 2, bezoar 0.4, musk 0.2, American ginseng 4; Dandelion 4, Hedyotis diffusa 5, Solanum nigrum 6, Forsythia 3, Pangolin 3, Flea 4, Chuanbei 3, Chishao 4, Tianding 2, Prunella vulgaris 3, Kelp 4, Fern root 4, Angelica 5, Rehmannia glutinosa 4, white peony root 4, salvia miltiorrhiza 4, rhubarb 2, capillary wormwood 4, geranium seed 4, soil tuckahoe 3, star anise lotus 4. 3、根据权利要求1所述的组合物,其特征在于其中的犀角用水牛角10-15重量份代替,且作为第(2)组原料。3. The composition according to claim 1, wherein rhino horn is replaced by 10-15 parts by weight of buffalo horn, and is used as the raw material of group (2). 4、根据权利要求2所述的组合物,其特征在于其中的犀角用水牛角15重量份代替,且作为第(2)组原料。4. The composition according to claim 2, wherein rhino horn is replaced by 15 parts by weight of buffalo horn, and is used as the raw material of group (2). 5、制备根据权利要求1、2、3或4中任一权利要求所述的中药组合物的方法,其特征在于将第(1)组原料粉碎;将第(2)组原料用常规方法煎成汤剂,浓缩干燥后,与第(1)组原料混合,制成片剂、散剂、冲剂或胶囊,或与第(1)组原料混合后,加蜜制成丸剂。5. The method for preparing the traditional Chinese medicine composition according to any one of claims 1, 2, 3 or 4, characterized in that the raw materials of the (1) group are pulverized; the raw materials of the (2) group are decocted by conventional methods Decoction, concentrated and dried, mixed with the raw materials of (1) to make tablets, powders, granules or capsules, or mixed with the raw materials of (1), added with honey to make pills. 6、一种治疗癌症的中药组合物,其特征在于它是由醋大戟2-3重量份和米炒斑蝥0.05-0.06重量份制成胶囊。6. A traditional Chinese medicine composition for treating cancer, which is characterized in that it is made into capsules by 2-3 parts by weight of vinegar spurge and 0.05-0.06 parts by weight of rice-fried mylabris. 7、一种治疗癌症的中药组合物,其特征在于它是由以下重量配比的原料:犀角2、牛黄0.4、麝香0.2、西洋参4-5制成散剂。7. A traditional Chinese medicine composition for treating cancer, which is characterized in that it is made into a powder made of the following raw materials in the following weight ratio: rhino horn 2, bezoar 0.4, musk 0.2, and American ginseng 4-5. 8、一种治疗癌症的中药组合物,其特征在于它是由以下重量配比的原料:山慈姑3-6、板蓝根5-10、蒲公英5-10、白花蛇舌草10-15、龙葵10-15、连翘5-10、穿山甲3-6、蚤休3-15、川贝3-10、赤芍5-10、天丁2-5、夏枯草3-10、昆布5-15、蕨根5-15、当归5-15、熟地5-15、白芍5-15、丹参5-15、大黄2-15、茵陈5-15、天葵子5-10、土茯苓5-10、八角莲3-10制成的汤剂。8. A traditional Chinese medicine composition for treating cancer, characterized in that it is composed of the following raw materials in the following weight ratio: Arthia chinensis 3-6, Radix isatidis 5-10, Dandelion 5-10, Hedyotis diffusa 10-15, Solanum nigrum 10-15, Forsythia 5-10, Pangolin 3-6, Flea Xiu 3-15, Chuanbei 3-10, Chishao 5-10, Tianding 2-5, Prunella vulgaris 3-10, Kelp 5-15, Fern root 5-15, Angelica 5-15, Rehmannia glutinosa 5-15, Paeoniae Alba 5-15, Salvia miltiorrhiza 5-15, Rhubarb 2-15, Capillary 5-15, Tiankui 5-10, Smilax 5-10 , the decoction that star anise lotus 3-10 is made. 9、根据权利要求7所述的组合物,其特征在于其中的犀角用水牛角10-15重量份代替,且作为第(2)组原料。9. The composition according to claim 7, wherein rhino horn is replaced by 10-15 parts by weight of buffalo horn and used as the raw material of group (2).
CNB011182229A 2001-05-23 2001-05-23 A kind of traditional Chinese medicine composition for treating cancer Expired - Fee Related CN1141126C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB011182229A CN1141126C (en) 2001-05-23 2001-05-23 A kind of traditional Chinese medicine composition for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB011182229A CN1141126C (en) 2001-05-23 2001-05-23 A kind of traditional Chinese medicine composition for treating cancer

Publications (2)

Publication Number Publication Date
CN1386524A true CN1386524A (en) 2002-12-25
CN1141126C CN1141126C (en) 2004-03-10

Family

ID=4663044

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011182229A Expired - Fee Related CN1141126C (en) 2001-05-23 2001-05-23 A kind of traditional Chinese medicine composition for treating cancer

Country Status (1)

Country Link
CN (1) CN1141126C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101007056B (en) * 2006-01-24 2012-02-29 江苏康缘药业股份有限公司 An antitumor medicinal composition and its preparation method
CN102397476A (en) * 2011-11-30 2012-04-04 牛德兴 Traditional Chinese medicine liniment for treating acute herpes zoster

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100400088C (en) * 2004-05-28 2008-07-09 张海峰 Anticancer medicine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101007056B (en) * 2006-01-24 2012-02-29 江苏康缘药业股份有限公司 An antitumor medicinal composition and its preparation method
CN102397476A (en) * 2011-11-30 2012-04-04 牛德兴 Traditional Chinese medicine liniment for treating acute herpes zoster
CN102397476B (en) * 2011-11-30 2013-04-03 牛德兴 Chinese medicinal pigmentum for treating acute herpes zoster

Also Published As

Publication number Publication date
CN1141126C (en) 2004-03-10

Similar Documents

Publication Publication Date Title
CN100563690C (en) A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc
CN104758659A (en) Traditional Chinese medicine paste for treating muscle and bone diseases
CN101926878B (en) Chinese medicinal composition for treating osteoarthritis and preparation method thereof
CN113813347A (en) Preparation method and process of compound paclitaxel anti-tumor capsule tablet
CN103948787A (en) Traditional Chinese medicine composition for treating odontalgia and preparation method thereof
CN100336527C (en) Medicine for treating celevical vertebra disease
CN100374147C (en) Traditional Chinese medicine preparation for treating mammary gland hyperplasia
CN1386524A (en) A Chinese medicinal composition for treating cancer
CN104758440A (en) Traditional Chinese medicine for treating ischialgia
CN1051471C (en) A kind of pharmaceutical composition for treating osteoporosis
CN107320698A (en) A kind of Chinese medicine compound prescription for treating person in middle and old age's nerve root cervical vertebra sickness and its application
CN1063650C (en) Chinese medicinal pill for curing rheumatism and rheumatoid disease and its preparation method
CN1217202A (en) Medicine for treating rheumatic diseases
CN102836276B (en) Bone spur softening pill for treating osteoarthritis
CN1312085A (en) Dermatosis treating medicine
CN101502583A (en) Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof
CN1090503C (en) Medical capsule for treating rheumatism and building up body and its preparing process
CN1127664A (en) External use medicinal bag for treating acute and chronic gastritis and cholecystitis, and preparing method thereof
CN114272329B (en) Traditional Chinese medicine composition for treating liver and kidney deficiency type cervical spondylosis, preparation and application
CN104825768A (en) Traditional Chinese medicine oral liquid for treating scrofula and preparation method thereof
CN1261123C (en) Chinese medicine preparation pus drawing out plaster for treating pasteur cystic, furuncle, furunculosis and carbuncle
CN114099582B (en) A topical Chinese medicinal composition for treating bone diseases, and its preparation method
CN1054052C (en) Comedo-elimination preparation
CN104547512B (en) A kind of pharmaceutical composition for treating disease of pharynx and preparation method thereof
CN101361889A (en) Traditional Chinese medicine capsule for treating psoriasis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee